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Summary
Objective: To assess the diagnostic and therapeutic difficulties in patients with
epilepsy who had never come into contact with specialist services.
Methods: Assessment was offered to 676 patients diagnosed as having epilepsy and
receiving anti-epileptic drug therapy (AED), who had no previous contact with the
local epilepsy services. Two hundred and seventy-five patients gave consent and
attended for reassessment. We identified the proportion of patients (a) who had
previously seen a neurologist, (b) in whom the diagnosis of epilepsy was not secure, (c)
in whom planned AED withdrawal could be considered (d) in whom seizure control
could be improved.
Results: 53/275 (19.3%) of those attending for review had previously been seen by a
neurologist. 87/275 (31.6%) patients ultimately received continued specialist care.
Diagnostic doubt was expressed in 3/53 (5.6%) and 42/222 (18.9%) of patients
diagnosed by neurologist and non-specialist, respectively.
Of 133/219 (60.7%) of patients whose epilepsy was in remission, only 6 elected to
withdraw or change medication. Of 18 patients with diagnostic doubt who accepted
follow-up, 12 successfully stopped treatment.
17/55 (30.9%) patients with active epilepsy (10 partial, 7 generalised) achieved at
least a 1 year remission consequent upon treatment in this clinic. In 15 cases this was a
first ever remission.
Conclusion: Approximately 55% of the population of adults receiving treatment for
epilepsy have never received specialist advice. Reassessment of these patients
uncovers diagnostic uncertainty, failure to classify (leading to sub-optimal therapy)
and lack of information and advice about all aspects of epilepsy care.* Corresponding author. Tel.: +44 141 232 7539; fax: +44 201 2509.
E-mail address: johnpaul.leach@sgh.scot.nhs.uk (J.P. Leach).
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Epilepsy is one of the commonest neurological con-
ditions1,2 with an estimated prevalence of epilepsy
in the UK of 0.7%. For each of the 350,000 affected
people, this diagnosis carries associated medical
and social sequelae. Across three decades, govern-
ment-sponsored reports from Reid3 to Kitson4
recommend that all patients with suspected new
epilepsy should see a neurologist or other specialist
for accurate diagnosis and optimal management.
Single5 and multi-practice audits6—8 and a large
national survey2 indicate that most patients have
been seen in a hospital clinic but the proportion
diagnosed and managed by specialists remains
unclear. The vast majority of patients are quickly
discharged to primary care where subsequent fol-
low-up arrangements are widely reported to be
inadequate.5,7,8
Documented consequences of this approach to
the care of people with a common chronic disorder
include misdiagnosis5,9,10 inadequate classification
and sub-optimal therapy5,6,9 unnecessary poor con-
trol and toxicity11 lack of knowledge about current
seizure control7,8 and necessity for long-term treat-
ment,7 widespread poor compliance, including inju-
dicious cessation of treatment6,12 and lack of
awareness about patients anxieties about many
aspects of their care.13 Given these problems, it
would appear important that all patients with the
label ‘epilepsy’ require specialist assessment.
The afore-mentioned studies were incomplete:
data were obtained from case-note review or per-
sonal review by GP but rarely included direct spe-
cialist support.6,10 Additionally, the larger studies7,8
were never designed to complete the audit cycle
and the reporting of intervention and subsequent
outcome is unique.10
Our original project involved the individual
review, by a specialist registrar with interest in
epilepsy (JPL or AN), of 275 patients with subse-
quent follow-up in a consultant-led epilepsy clinic
in 87 cases. The intention was to estimate the
therapeutic and diagnostic gaps in a District Gen-
eral Hospital catchment area with an establishedepilepsy clinic. The local and national implications
of our findings for the future planning of services is
discussed.
Methods
The partners in all 26 general practices located
within the Wrexham Maelor hospital catchment area
(of approximately 200,000 people) accepted the
invitation to participate. All patients with a diag-
nosis of epilepsy, on anti-epileptic drug therapy,
were identified from practice records. Letters were
sent from the practice requesting permission to
release details to the investigating team. Once
signed consent was received, patients were invited
to attend for review of their condition.
One hundred and eighty-three children under 16
years of age and 357 adults already attending the
local epilepsy clinic were excluded from further
review. After several frail individuals attended we
excluded the remaining 123 patients aged over 80
years.
Initial assessments were undertaken by experi-
enced specialist registrars; JPL (249) and AN (26).
Data collection included history of seizure disorder,
results of previous investigations and nature of all
current and previous treatments. Information was
obtained from patients, carers, relatives, and any
existing correspondence.
Diagnosis of epilepsy was categorised as secure or
doubtful. Diagnostic doubt, based on clinical
grounds, was expressed if (a) there was an alter-
native explanation for the attacks or (b) insufficient
evidence to support a confident diagnosis of epi-
lepsy. Frequency, or remission, of events were
recorded, with remission defined as at least 12
months event-free. Patients whose epilepsy was
in remission received individualised estimates of
risk of relapse on drug withdrawal.14
It emerged that many patients had attended seek-
ing specific information and their concerns were
recorded. After consultation, consultant follow-up
was arranged if a treatment change was offered and
accepted. Otherwise, patients were discharged.The development of integrated services for people with epilepsy (PWE) must take
account of this hidden need. The new General Medical Services contract for general
practitioners will bring this need to our attention, and our experience will help
predict the measures required to deal with the under-treatent and mistreatment of
this group. The majority of PWE, not currently receiving shared care, merit reassess-
ment and approximately one-third will require continued specialist care. Existing
services do not have the capacity to process a marked increase in rate of referral. This
project informs prioritisation of referrals and service reorganisation.
# 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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Table 1 Estimation of proportion of prevalent popu-
lation never seen by specialist.
Catchment population 194187
Patients with epilepsy (prevalence) 1339 (0.69%)
Adults (>16 years) with epilepsy 1156
Never attended local epilepsy clinic 799
Eligible for reassessment (after
exclusion of 123 people aged
over 80 years)
676
Attended for reassessment 275
Number (%) attending who had
previously been seen by a
neurologist
53 (19.3%)
The denominator is adults with epilepsy (1156). Three hun-
dred and fifty-seven were attending local epilepsy clinic.
19.3% of those attending for review had previously seen a
neurologist. 19.3% of all adults not attending the epilepsy
clinic is 154. 357 + 154 = 511 patients had ever seen specialist.
Therefore, assuming representative sample (see discussion),
the remainder 645/1156 (55.8%) had never seen a specialist.
Table 4a Outcome: diagnostic uncertainty.
Outcome Number
Positive: stopped AEDs, no events 9a
Stopped AEDs, events–—not seizures 4
Neutral: stopped AEDS then DNA 2
Treatment continued 3
Negative: reduced AEDs, definite seizure 1
Total 19
a Includes one patient with single seizure.Results
The prevalence of epilepsy in this catchment area of
0.69% is consistent with UK estimates.3 275/676
(40.7%) of those eligible attended for reassessment,
of whom 53/275 (19.3%) had been previously seen by
a neurologist. Assuming this sample to be represen-
tative of the whole prevalent population we esti-
mate that 56% of adults with epilepsy had never
received specialist advice (Table 1).
Initial categorisation of patients and recom-
mended follow-up is shown in Table 2. ConsultantTable 2 Follow-up according to initial assessment categor
Category Number Offered follow-u
Single seizure 12 10
Diagnostic doubt 45 38
Epilepsy (remission) 133 59
Epilepsy (active) 86 78
Total 275 177 (64.3%)
a One patient with definite epilepsy who had tonic-clonic seizure
b One patient initially considered to be in remission but, after re
c Two patients initially considered to have active epilepsy but, a
Table 3 Remission rate according to initial classification o
Classification of epilepsy Diagnosed by neurologist
Partial 23/34 (67.6%)
Idiopathic generalised 7/10 (70%)
Symptomatic generalised 0/2
Unclassified 2/4 (50%)
Total 32/50 (64%)opinion differed significantly from that of the spe-
cialist registrar in only 4/87 cases.
Diagnostic doubt was expressed in 3/53 (5.6%)
and 42/222 (18.9%) of patients diagnosed by neu-
rologists and non-specialists respectively. Nineteen
of these patients continued to experience events.
Sixteen patients who were event-free and seven
with ongoing attacks elected to remain on treat-
ment and were not followed up. 9/31 women whose
diagnosis was questioned had received AEDs during
their child-bearing years.
The overall remission rate was 133/219 (60.7%).
Remission rates in patients diagnosed by neurolo-
gists and non-specialists were broadly similar,
although failure to recognise the idiopathic general-
ised epilepsies15 resulted in poorer than expected15
outcome in some individuals (Table 3).
87/275 (31.6%) patients ultimately received con-
tinued specialist care. Medium-term outcomes are
displayed in Tables 4a—4c, respectively. Specific
details of those achieving remission are given in
Table 5.y.
p Accepted follow-up Continued follow up
6 1
22 18a
23 13b
57 55c
108 (39.2%) 87 (31.6%)
on reduction of therapy.
view, found to have active epilepsy.
fter review, thought to be in remission.
f epilepsy.
Diagnosed by non-specialist Total
77/126 (61.1%) 100/160 (62.5%)
11/23 (47.8%) 18/33 (54.5%)
2/5 (40%) 2/7 (28.6%)
11/15 (73.3%) 13/19 (68.4%)
101/169 (59.8%) 133/219 (60.7%)
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Table 4b Outcome: epilepsy in remission.
Outcome Number
Positive: stopped AEDs, no relapse 2
Changed treatment, side effects resolved 4
Neutral: treatment continued 5
Not in remission 1
Negative: stopped AEDs, relapse 1
Total 13
Table 4c Outcome: active epilepsy.
Outcome Number
Positive: new remission >1 year 17
Improveda 20
Neutral: unchanged 11
Uncertain–—lost to follow-up 4
Epilepsy not active 2
Negative: worseb 1
Total 55
a Worthwhile reduction in seizure frequency or severity, or
resolution of side effects.
b Transient deterioration in seizure control.Discussion
The existing literature indicates the likelihood of
significant deficiencies in the care of patients with
epilepsy managed in the community. That the
extent of these problems remains unknown, repre-
sents an impediment to the planning of service
provision locally and nationally.2
Previous community-based audits have usually
been GP-led, with little specialist support, but
reporting benefit in small numbers of patients.
The Community Awareness and Resources for Epi-
lepsy (CARE) project10 involved collaboration
between primary and secondary care but outcomeTable 5 Epilepsy type and treatment change leading to re
Epilepsy
syndrome
Patient Longest
previous
remission
Current
seizure
types
Ex
tr
Cryptogenic
partial
AB 10 months SGTC PH
SH 3 months CP, SGTC PH
RH 1 month CP, SGTC CB
AJ 3 months CP PH
JJ 6 months SP CB
RJ 1 month SGTC PH
LW 1 month CP, SGTC CB
Symptomatic
partial
HA 3 months CP PH
JC 6 months SP PH
AR 6 months CP, SGTC VP
Idiopathic
generalised
GF 1 month Myoclonus,
absences,
PGTC
PH
LF Days Absences VP
SG 5 months Myoclonus VP
JL 5 Years Myoclonus,
PGTC
VP
DP 1 month Myoclonus PH
KP 1 year Myoclonus,
PGTC
PB
Symptomatic
Generalised
GE 2 months PGTC VP
SP: simple partial; PHT: phenytoin; CP: complex partial; PB: phe
carbamazepine; PGTC: primary generalised tonic-clonic; VPS: sodiuwas reported only in terms of misdiagnosis. Larger
projects7,8 were not designed to influence patient
outcome or inform service development.
Our study is original in several respects; patients
volunteered to be reviewed, initial and subsequent
assessment was conducted by trained specialists,
and positive outcomes are reported in patients with
active epilepsy. While all aspects of care of PWE are
under scrutiny, these findings inform clinicians
about the extent of unmet need and the implica-
tions for service development and re-organisation.mission.
isting
eatment
Treatment change Duration
new remission
T 100 mg tds PHT 300 mg od 15 months
T + PB LTG replaced PB
then PHT withdrawn
28 months
Z 1.2 g TPM added 22 months
T Switchover to TPM 42 months
Z 800 mg Increased to 1 g 18 months
T LTG added 25 months
Z 100 mg Increased to 600 mg 14 months
T LTG added 24 months
T Switchover to LTG 27 months
S + PHT TPM replaced PHT 31 months
T Switchover to TPM 24 months
S + LTG VPS dose increased 19 months
S 1.0 g Increased to 1.4 g 42 months
S LTG added 41 months
T Switchover to TPM,
then VPS, then LTG
32 months
+ PHT VPS replaced PHT 17 months
S + LTG LTG dose increased 12 months
nobarbitone; SGTC: secondary generalised tonic-clonic; CBZ:
m valproate; LTG: lamotrigine; TPM: topiramate.
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There is no gold standard for the diagnosis of epi-
lepsy and there will often be uncertainty about
diagnoses made many years ago. However, the level
of agreement between specialist registrar and con-
sultant was high and the reporting of negative out-
comes is evidence that this was not contrived.
Importantly, 12/18 patients with alternative diag-
noses stopped treatment without problems.
The rate of misdiagnosis (16.3%) is within the
range of 5 and 23% reported in community-based
studies.6,10 No-one can completely avoid mistakes
but doctors with appropriate training will be less
likely to misdiagnose epilepsy. The relative rates of
misdiagnosis made by neurologists (5.6%) and non-
specialists (19.3%) lends support to this assertion. A
low rate of specialist misdiagnosis has been con-
firmed by the rate of misdiagnosis in cases entered
into Standard And New Anti-epileptic Drug (SANAD)
trial16 between January 1999 and January 2002 by a
single specialist (DS); 5/278 (1.8%) new patients
have subsequently been withdrawn due to misdiag-
nosis.
Epilepsy in remission
The overall remission rate of 60.7% is consistent with
published literature.7,8 That there was no significant
difference in outcome for patients with partial
epilepsies, whether diagnosed by neurologists or
not, can be explained by the facts that their prog-
noses are mainly dependent upon aetiology and that
all conventional AEDs possess similar efficacy
against these seizure types.17 The poorer than
expected outcome in patients with idiopathic gen-
eralised epilepsies (IGE) may have been predicted,
since these specifically require treatment with
broad spectrum AEDs.15
The MRC Anti-epileptic Drug Withdrawal Study14
produced data which allows individualised counsel-
ling about the risk of relapse on drug withdrawal.
These had not been previously used to inform the
need to continue treatment in our patients. In
keeping with previous experience18 most patients
elected to stay on medication following counselling
(usually related to concerns about driving eligibil-
ity). However, four such patients chose to stop
treatment with subsequent resolution of AED-
related side effects.
Active (refractory) epilepsy
Smith et al.9 assessed 94 patients referred to a
specialist in 1991 for management of ‘drug-resistant
epilepsy’. Twelve (13%) did not have epilepsy and16/80 (20%) who did have epilepsy were rendered
seizure-free by surgery (4) or by change of medica-
tion (12). Nearly a decade later, from a sample of
patients in the community in whom hospital review
was not planned, we find that 17/55 (30.7%) with
active epilepsy obtained at least 1 year seizure-
freedom following consultation with a specialist.
This was achieved by either optimising use of con-
ventional drugs (n = 5) or following introduction of
newer agents (n = 12). It is well-recognised that use
of the newer agents is largely restricted to specialist
practice.17 For 15/17 this represented a first ever
remission
Patients require further information
Many patients attended the clinic seeking specific
information: the commonest questions concerned
the possibility of drug withdrawal (58 patients),
driving regulations (27 patients), reproduction or
fertility (14 patients), doubts over diagnosis (3
patients), side effects and interactions of long-term
AEDs (4 patients), and safety including alcohol con-
sumption (3 patients). These findings confirm that
patients will benefit if specialists (either consultants
or specialist nurses) can address specific concerns
about their condition19. Despite preferring to
receive care from their GP2 patients are very reluc-
tant to discuss their concerns with the family doc-
tor.12,13 We know that better understanding of
epilepsy among patients has tangible psychological
benefits and delivery of this knowledge is a key role
of the epilepsy specialist nurse.20
An estimate of unmet need in the whole
prevalent population
One can only speculate about the reasons why 401/
676 (59.4%) patients did not give consent for
further review. We can assume that the majority2
of these will be seizure-free, with most of these
tolerating their treatment. However, a significant
minority will have active epilepsy and evidence
suggests that some patients with chronic epilepsy
are reluctant to access services.21 Indeed Taylor
(1987)22 reports that people who would benefit
most from intervention have to be ‘sought out’.
We cannot be certain about the characteristics of
those not attending since no consent was given for
further assessment.
If we assume that our sample is representative,
then review of the entire population, would produce
the following findings; a period of continued care in
specialist clinic (215), removal of epilepsy label and
cessation of treatment (30), in remission–—with sub-
sequent withdrawal or change of therapy (15), and
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Box 1. Reorganisation of care for people with label ‘epilepsy’
Early review by consultant Active epilepsy especially if (a) tonic-clonic seizures or (b) out-dated
treatment regime, e.g. low doses of phenytoin and phenobarbitone
Diagnosis insecure especially if still having events; may have treatable
cardiovascular condition
Early review by specialist nurse All women of child-bearing age unless (a) clear documentation that
already received counselling and open access to an epilepsy/neurology
service or (b) incapable of having children
Routine review by consultant or nurse Event-free and wishing to consider drug withdrawal
All referrals To be accompanied by (a) relevant previous correspondence
and (b) an eye-witness for attacks
Discharge from secondary care 1 year (maximum 2 year) remission; should have received counselling
about pros and cons of drug withdrawal
Active, but stable, epilepsy where treatment options exhausted
All discharged patients to be accompanied by (a) request for annual
review in community and (b) explicit guidance on re-referral
Annual review in community Event-free, tolerating medication and driving
Active epilepsy refusing referral; continue to document
condition and offer referralconfirmed active epilepsy achieving first ever remis-
sion (37).
The ‘Best Case’ scenario is that those who did not
respond are completely well. In this case, there
would be 401 patients in remission, free from side-
effects and well-informed about their condition. In
this unlikely event, the figures among those who did
respond still represent significant unmet need within
the District General Hospital catchment area.
We know that the Wrexham Maelor Hospital has
one of only 17 District General Hospital-based epi-
lepsy clinics in the country.23While our results can be
extrapolated nationwide, this greater than normal
service provision ensures that this will be an under-
estimate of the unmet need in most other areas.
Implications for service re-organisation
The care of PWE is currently under scrutiny; epilepsy
is one of ten clinical indicators in the quality and
outcomes framework of the new GMS contract.
While this contract requires only documentation
of patients’ seizure control and medication, pub-
lished guidelines24 include explicit standards of
care. Furthermore, the National Primary and Care
Trust Development Programme explicitly defines
Primary Care Trust competencies including ‘working
towards guidelines’.
Consequently, as practices create disease regis-
ters, primary care, as a whole, will ‘discover’ hun-
dreds of thousands of patients from which tens of
thousands will merit re-assessment. Prioritisation of
referrals will be difficult, and existing secondary
care does not have the capacity to process a markedrise in number of referrals of people with the label
‘epilepsy’. Meanwhile, however, our project should
help plan provision of such services and may form a
basis for coherent advice on targeting and prioriti-
sation of referrals (Box 1).
Priority should be given to patients with continu-
ing attacks–—whether to allow manipulation of AEDs
or exclusion of other treatable conditions25. All
women of child-bearing age should be counselled
about fertility and teratogenesis. People who are
event-free, whether the diagnosis is secure or not,
can be seen less urgently. The resultant referrals
may provide a negative impact on local neurology
services, with a potential later offset following the
discharge of recently diagnosed patients achieving
remission. Nevertheless, major resource shortfalls
will be identified, creating local cases for more
specialist input including, ideally, GPs with specia-
list interest.
Conclusion
The responses gained from around 40% of patients
with epilepsy in the community show that even in an
area with an established epilepsy clinic there is
significant unrecognised and unmet need within
the prevalent population. Nationally there is a large
reservoir of misdiagnosed, sub-optimally treated
and ill-informed patients. Our experience shows
that patients benefit positively from exposure to
specialist services.
The planning of future service provision must take
account of this hidden need. The identification and
520 J.P. Leach et al.assessment of those patients meriting review
requires the co-ordinated efforts of primary and
secondary care on behalf of purchasers (Primary Care
Trusts, local health boards) and providers, respec-
tively. It would be perfectly feasible for lead GPs in
large practices2 or Primary Care Trust-appointed GPs
to create disease registers from which, with specia-
list guidance, patients can be identified for manage-
ment in community or medical or nursing review.
Inaction is not an option, but constructive action will
require careful planning and resource allocation.References
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